The individual tumors of a xenograft line have identical genetic background in contrast to individual tumors in cervical cancer patients, and consequently, the observations reported here show that it is highly unlikely that the expression of HIF-1α or CAIX can be useful biomarkers of tumor hypoxia and/or outcome of chemoradiotherapy in locally advanced cervical carcinoma. The gene discussed is CA9; the disease is neoplasm.